Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Opioid Policy At US FDA: Gottlieb Seeks More Activist Role To Combat Abuse

Executive Summary

‘Dramatic action’ needed to curb opioid epidemic, commissioner-nominee says, including potentially a cross-center approach to evaluating drugs and devices for pain, and new nomenclature for formulations currently labeled as abuse deterrent.


Related Content

Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals
Gottlieb's Confirmation: He's Willing To Disagree With Trump, Sec. Price
Abuse Deterrence: US Exclusivity Update May Ride User Fee Coattails
Combo Products Won't Get Special Review Pathway At US FDA Anytime Soon
Cures Bill Authorizes 'Intercenter Institutes,' But Will US FDA Create Them?
Opioid Clinical Efficacy Standards Need Rethinking, FDA Panel Says
FDA's Opioid Action Plan Could Clear Califf Nomination Roadblock
Califf Nomination Suffers 'Pile On': What Can FDA Do To Break Logjam?
Keeping Track: Neurology And Pain Products Keep FDA Occupied
FDA Clears Zohydro Single-Entity Hydrocodone Without Abuse Deterrence Properties


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts